About Xbrane Biopharma AB 
Xbrane Biopharma AB
Pharmaceuticals & Biotechnology
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
Company Coordinates 
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Management
Designation
Mr. Anders Tullgren
Independent Chairman of the Board
Mr. Giorgio Chirivi
Independent Director
Mr. Ivan Cohen-Tangui
Independent Director
Prof. Peter Edman
Independent Director
Ms. Eva Nilsagard
Independent Director
Ms. Karin Wingstrand
Independent Director
Revenue and Profits:
Net Sales:
40 Million
(Quarterly Results - Jun 2025)
Net Profit:
-15 Million
Pharmaceuticals & Biotechnology
SEK 208 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.16
-12.41%
0.35






